title: Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller.
abstract: Compared with human platelets, rodent platelets are less responsive to peptides and peptidomimetics containing an arginine-glycine-aspartic acid (RGD) motif. Using chimeric human-rat alphaIIbbeta3 molecules, we found that this difference in Arg-Gly-Asp-Ser (RGDS) sensitivity was the result of amino acid substitutions at residues 157, 159, and 162 in the W3:4-1 loop and an Asp-His replacement at residue 232 in the W4:4-1 loop of the alphaIIb beta propeller. Introducing the entire rat W3:4-1 and W4:4-1 loops into human alphaIIbbeta3 also decreased the inhibitory effect of the disintegrins, echistatin and eristostatin, and the alphaIIbbeta3 antagonists, tirofiban and eptifibatide, on fibrinogen binding, whereas the specific point mutations did not. This suggests that RGDS interacts with alphaIIb in a different manner than with these small molecules. None of these species-based substitutions affected the ability of alphaIIbbeta3 to interact with RGD-containing macromolecules. Thus, human von Willebrand factor contains an RGD motif and binds equally well to adenosine diphosphate-stimulated human and rodent platelets, implying that other motifs are responsible for maintaining ligand binding affinity. Many venoms contain RGD-based toxins. Our data suggest that these species amino acids differences in the alphaIIb beta-propeller represent an evolutionary response by rodents to maintain hemostasis while concurrently protecting against RGD-containing toxins.
authors.affiliation: Division of Hematology, Children's Hospital of Philadelphia, PA19104, USA.
authors.forename: Ramesh B
authors.initials: RB
authors.lastname: Basani
authors.forename: Hua
authors.initials: H
authors.lastname: Zhu
authors.forename: Michael A
authors.initials: MA
authors.lastname: Thornton
authors.forename: Cinque S
authors.initials: CS
authors.lastname: Soto
authors.forename: William F
authors.initials: WF
authors.lastname: Degrado
authors.forename: M Anna
authors.initials: MA
authors.lastname: Kowalska
authors.forename: Joel S
authors.initials: JS
authors.lastname: Bennett
authors.forename: Mortimer
authors.initials: M
authors.lastname: Poncz
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000595:Amino Acid Sequence; D000818:Animals; D002460:Cell Line; D017124:Conserved Sequence; D006224:Cricetinae; D000077542:Eptifibatide; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D010455:Peptides / Q000378:metabolism*; D010974:Platelet Aggregation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D011485:Protein Binding; D051381:Rats; D011994:Recombinant Proteins / Q000378:metabolism; D016415:Sequence Alignment; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000378:metabolism
chemical_list: D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D014443:Tyrosine; D000244:Adenosine Diphosphate; D005340:Fibrinogen; D000077466:Tirofiban; D000077542:Eptifibatide